Zevra Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Zevra Therapeutics Inc ZVRA.OQ reported a quarterly adjusted loss of 6 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -40 cents. The mean expectation of seven analysts for the quarter was for a loss of 19 cents per share. Wall Street expected results to range from -24 cents to -12 cents per share.

• Revenue rose 495.6% to $20.40 million from a year ago; analysts expected $16.96 million.

• Zevra Therapeutics Inc's reported EPS for the quarter was a loss of 6 cents​.

• The company reported a quarterly loss of $3.1 million.

• Zevra Therapeutics Inc shares had risen by 3.5% this quarter and lost 7.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 157.1% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Zevra Therapeutics Inc is $22.00

This summary was machine generated from LSEG data May 13 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)